Possibilities of targeted therapy for myelofibrosis: Moscow experience
Background. For many years the primary aim of treatment strategy for ph-negative myeloproliferative neoplasms has been to restrain disease progression, with lasting relief and management of symptoms to improve patients’ quality of life. Generally, this did not lead to a significant increase in life...
Main Authors: | O. Yu. Vinogradova, M. M. Pankrashkina, D. I. Shikhbabaeva, M. V. Chernikov, A. L. Neverova, V. L. Ivanova, E. A. Nikitin, E. V. Usikova, V. V. Ptushkin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2022-11-01
|
Series: | Онкогематология |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/593 |
Similar Items
-
Molecular markers as possible efficacy predictors of targeted therapy for myelofibrosis: single-center study
by: O. Yu. Vinogradova, et al.
Published: (2023-12-01) -
Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
by: O. Yu. Vinogradova, et al.
Published: (2024-09-01) -
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
by: Bewersdorf JP, et al.
Published: (2019-12-01) -
Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
by: M. S. Fominykh, et al.
Published: (2016-08-01) -
Treatment Strategies Used in Treating Myelofibrosis: State of the Art
by: Massimo Martino, et al.
Published: (2024-10-01)